Evidence map›Paper›PMID 40835772›Full record

ArticleInternational journal of clinical oncology2025

Impact of body mass index on the efficacy of immune combination therapy in metastatic renal cell carcinoma: a multicenter study in Japan.

Toshiki Anami, Takanobu Motoshima, Yuto Matsushita, Takahiro Kojima, Shimpei Yamashita, Hisanori Taniguchi, Keisuke Monji, Ryo Ishiyama, Yoshihide Kawasaki, Takuma Kato and 9 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Observational
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Toshiki AnamiDepartment of Urology, Faculty of Life Sciences, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Chuouku, Kumamoto, 860-8556, Japan. toshiki_anami@yahoo.co.jp.ORCID http://orcid.org/0000-0002-7646-6267
Takanobu MotoshimaDepartment of Urology, Faculty of Life Sciences, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Chuouku, Kumamoto, 860-8556, Japan.
Yuto MatsushitaDepartment of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan.
Takahiro KojimaDepartment of Urology, Aichi Cancer Center, Aichi, Japan.
Shimpei YamashitaDepartment of Urology, Wakayama Medical University, Wakayama, Wakayama, Japan.
Hisanori TaniguchiDepartment of Urology and Andrology, Kansai Medical University, Osaka, Japan.
Keisuke MonjiDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Ryo IshiyamaDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Yoshihide KawasakiDepartment of Urology, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Takuma KatoDepartment of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Shuichi TataranoDepartment of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Kimihiko MasuiDepartment of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Eijiro NakamuraDepartment of Urology, National Cancer Center Hospital, Tokyo, Japan.
Tomoyuki KanekoDepartment of Urology, Teikyo University School of Medicine, Tokyo, Japan.
Makito MiyakeDepartment of Urology, Nara Medical University, Nara, Japan.
Hiroshi KitamuraDepartment of Urology, Faculty of Medicine, University of Toyama, Toyama, Japan.
Hideaki MiyakeDepartment of Urology, Kobe University Graduate School of Medicine, Hyogo, Japan.
Tomomi KambaDepartment of Urology, Faculty of Life Sciences, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Chuouku, Kumamoto, 860-8556, Japan.
Japan Urological Oncology Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRenal cell carcinoma (RCC) is a major urologic malignancy worldwide, with obesity recognized as a known risk factor. Interestingly, a higher body mass index (BMI) has been associated with improved outcomes in immunotherapy, a phenomenon termed the "obesity paradox." This study investigates the influence of BMI on the effectiveness of immune combination therapies in Japanese patients with metastatic RCC.

methodsA retrospective study was conducted on 243 Japanese patients with metastatic RCC who received immune combination therapies between 2018 and 2022. Patients were stratified into two groups: non-overweight/obesity (BMI < 25 kg/m

resultsThere was no significant difference in PFS between the groups. However, the overweight/obesity group showed a trend toward longer OS, particularly in patients receiving IO-IO regimens (P = 0.011). In contrast, although no statistically significant difference was observed in the IO-TKI regimen, there was a trend toward prolonged OS in the non-overweight/obesity group. No significant differences in immune-related adverse events were observed between the groups.

conclusionHigher BMI may be associated with better outcomes in immune combination therapy, especially with IO-IO regimens. These findings suggest that BMI could be a useful factor in optimizing RCC treatment. Further research with larger cohorts is needed to confirm these results and understand the mechanisms behind the "obesity paradox."

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBody Mass IndexCarcinoma, Renal CellImmunotherapyKidney NeoplasmsObesityAdultAgedAged, 80 and overFemaleHumansJapanMaleMiddle AgedProgression-Free SurvivalRetrospective StudiesBody mass index (BMI)Immune combination therapyObesity paradoxRenal cell carcinoma (RCC)

Identifiers

PMID40835772
PMCPMC12474707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.